Botanix Pharmaceuticals Limited (ASX:BOT)
Australia · Delayed Price · Currency is AUD | Market Cap | 256.19M |
| Revenue (ttm) | 5.79M |
| Net Income (ttm) | -86.40M |
| Shares Out | 1.97B |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,556,018 |
| Average Volume | 7,744,479 |
| Open | 0.1250 |
| Previous Close | 0.1250 |
| Day's Range | 0.1250 - 0.1300 |
| 52-Week Range | 0.1050 - 0.5350 |
| Beta | 1.02 |
| RSI | 41.24 |
| Earnings Date | Nov 25, 2025 |
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t... [Read more]
Financial Performance
In 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.
Financial StatementsNews
Botanix Pharmaceuticals taps investors for $40m; Euroz, E&P in tow
The ASX-listed company had Euroz Hartleys and E&P Capital offering shares at 33¢ each.
This media company’s share price is tipped to double
Lennox small caps manager Liam Donohue says he’s bullish on Botanix Pharmaceuticals and explains why he is eyeing up some former market darlings.